Ranbaxy Laboratories Ltd on Monday said Nihon Pharmaceuticals Industry Ltd, a JV between the company and Nippon Chemiphar Ltd, has launched its first co-developed product Vogseal 0.2mg and 0.3mg tablets in Japan.
The product, used for the treatment of diabetes, will be sold in Japan under the Ranbaxy or NPI label and marketed to doctors in hospitals as well as in clinics by the field forces of Nippon Chemiphar and NPI, Ranbaxy informed the Bombay Stock Exchange.
"We are delighted to introduce our first product in Japan, which is a reflection of our R and D strength and excellent cross functional teamwork.
"Together with our strategic partner, NC, we are committed to building our presence in this key market by providing quality generic alternatives," said Malvinder Mohan Singh, president and executive director, Ranbaxy Laboratories.
